search
Back to results

Bleeding in Laparoscopic Liver Surgery (MODELS)

Primary Purpose

Neuromuscular Blockade, Intraoperative Bleeding, Hepatic Cancer

Status
Recruiting
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Neuromuscular blockade
Sponsored by
Università Vita-Salute San Raffaele
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Neuromuscular Blockade focused on measuring liver surgery, bleeding, neuromuscular blockade, rocuronium, airway pressure

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients undergoing laparoscopic liver resection
  • Patients ≥ 18 years old
  • Patients willing to participate to the study and able to validly sign informed consent.

Exclusion Criteria:

  • Patients presenting a pre-operative platelet count < 50 x 109/L and/or patients with active pre-operative bleeding
  • Patients with planned requirement of continuous neuromuscular blockade monitoring (upon clinical judgement)
  • Known hypersensitivity / previous allergic reactions to study medications
  • Planned total intra-venous anesthesia technique
  • Pregnant or breastfeeding patients.

Sites / Locations

  • Ospedale San RaffaeleRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Deep neuromuscular blockade

Moderate neuromuscular blockade

Arm Description

During surgery, deep neuromuscular blockade will be achieved with the use of train of four (TOF) monitoring, aiming for a Post-Tetanic Count (PTC) = 0 or PTC = 1 and Train of Four Count (TOFC) = 0. TOF and PTC measurements will be performed every 15 minutes. Boluses of 0,1 mg/kg Rocuronium will be administered if monitored PTC is > 1. Complete neuromuscular blockade reversal at the end of surgery will be achieved with an i.v. bolus of Sugammadex (variable dose according to depth of residual blockade) if TOF ratio is ≤ 0.9. If TOF ratio is > 0.9, pharmacological neuromuscular blockade reversal can be avoided.

During surgery, a moderate neuromuscular blockade will be achieved with the use of train of four (TOF) monitoring. TOF and Post-Tetanic Count (PTC) measurements will be performed every 15 minutes. Boluses of 0,1 mg/kg Rocuronium will be administered if monitored TOF count is ≥ 1 and/or PTC > 5. Complete neuromuscular blockade reversal at the end of surgery will be achieved with an i.v. bolus of Sugammadex (variable dose according to depth of residual blockade) if TOF ratio is ≤ 0.9. If TOF ratio is > 0.9, pharmacological neuromuscular blockade reversal can be avoided.

Outcomes

Primary Outcome Measures

Total intra-operative blood loss
total blood loss at the end of surgery, measured in milliliters (ml) of blood inside the aspirator canister

Secondary Outcome Measures

Number of blood product units transfused
number of blood product units transfused from the experimental intervention until hospital discharge
Incidence of surgical revision
incidence of surgical revision
Airway peak and plateau pressures
airway pressures, as indicated by ventilator peak pressure (mmHg) and plateau pressure (mmHg) during surgery
Quality of surgical field
quality of surgical field as assessed by the surgeon with Leiden-Surgical Rating Scale (L-SRS), ranging from 1 (extremely poor conditions) to 5 (optimal conditions), higher scores meaning better outcome
Surgery and hepatic resection time
surgery and hepatic resection time

Full Information

First Posted
October 9, 2020
Last Updated
June 22, 2022
Sponsor
Università Vita-Salute San Raffaele
search

1. Study Identification

Unique Protocol Identification Number
NCT04609410
Brief Title
Bleeding in Laparoscopic Liver Surgery
Acronym
MODELS
Official Title
Bleeding in Moderate Versus Deep Neuro Muscular Blockade for Laparoscopic Liver Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
June 2022
Overall Recruitment Status
Recruiting
Study Start Date
October 30, 2020 (Actual)
Primary Completion Date
October 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Università Vita-Salute San Raffaele

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Blood loss during liver resection surgery affects patients morbidity, short and long-term mortality. Among non-surgical interventions to minimize intraoperative blood loss and perioperative blood products transfusion, maintaining conditions of low central venous pressure is considered as standard of care. In animals undergoing laparoscopic hepatectomy, reducing airway pressures represents a minimally invasive measure to reduce central venous pressure and therefore bleeding from the hepatic vein. Neuromuscular blocking agents are usually administered during anesthesia to facilitate endotracheal intubation and to improve surgical conditions: a deep level of neuromuscular blockade has already been shown to reduce peak airway pressures and plateau airway pressures in non-abdominal procedures. Such airway pressures reduction can potentially limit bleeding from hepatic veins during transection phase in liver surgery. The aim of the present study is to evaluate the impact of deep neuromuscular blockade on bleeding (as a consequence of reduced airway peak pressure and plateau pressure) in hepatic laparoscopic resections. Patients undergoing laparoscopic liver resection will be randomized to achieve, using intravenous Rocuronium, either a deep neuromuscular blockade (post-tetanic count = 0 and/or = 1 and train of four count = 0) or moderate neuromuscular blockade (train of four count ≥ 1 and/or post-tetanic count > 5) during surgery. Neuromuscular blockade measurements will be performed every 15 minutes. The primary endpoint is to assess the total blood loss at the end of the resection phase.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Neuromuscular Blockade, Intraoperative Bleeding, Hepatic Cancer
Keywords
liver surgery, bleeding, neuromuscular blockade, rocuronium, airway pressure

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
200 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Deep neuromuscular blockade
Arm Type
Experimental
Arm Description
During surgery, deep neuromuscular blockade will be achieved with the use of train of four (TOF) monitoring, aiming for a Post-Tetanic Count (PTC) = 0 or PTC = 1 and Train of Four Count (TOFC) = 0. TOF and PTC measurements will be performed every 15 minutes. Boluses of 0,1 mg/kg Rocuronium will be administered if monitored PTC is > 1. Complete neuromuscular blockade reversal at the end of surgery will be achieved with an i.v. bolus of Sugammadex (variable dose according to depth of residual blockade) if TOF ratio is ≤ 0.9. If TOF ratio is > 0.9, pharmacological neuromuscular blockade reversal can be avoided.
Arm Title
Moderate neuromuscular blockade
Arm Type
Active Comparator
Arm Description
During surgery, a moderate neuromuscular blockade will be achieved with the use of train of four (TOF) monitoring. TOF and Post-Tetanic Count (PTC) measurements will be performed every 15 minutes. Boluses of 0,1 mg/kg Rocuronium will be administered if monitored TOF count is ≥ 1 and/or PTC > 5. Complete neuromuscular blockade reversal at the end of surgery will be achieved with an i.v. bolus of Sugammadex (variable dose according to depth of residual blockade) if TOF ratio is ≤ 0.9. If TOF ratio is > 0.9, pharmacological neuromuscular blockade reversal can be avoided.
Intervention Type
Procedure
Intervention Name(s)
Neuromuscular blockade
Intervention Description
Neuromuscular blockade will be achieved via rocuronium intravenous administration and level will be monitored with train of four/post tetanic count monitoring
Primary Outcome Measure Information:
Title
Total intra-operative blood loss
Description
total blood loss at the end of surgery, measured in milliliters (ml) of blood inside the aspirator canister
Time Frame
Postoperative day 0
Secondary Outcome Measure Information:
Title
Number of blood product units transfused
Description
number of blood product units transfused from the experimental intervention until hospital discharge
Time Frame
Up to hospital discharge, an average of 5 days
Title
Incidence of surgical revision
Description
incidence of surgical revision
Time Frame
Up to hospital discharge, an average of 5 days
Title
Airway peak and plateau pressures
Description
airway pressures, as indicated by ventilator peak pressure (mmHg) and plateau pressure (mmHg) during surgery
Time Frame
Postoperative day 0
Title
Quality of surgical field
Description
quality of surgical field as assessed by the surgeon with Leiden-Surgical Rating Scale (L-SRS), ranging from 1 (extremely poor conditions) to 5 (optimal conditions), higher scores meaning better outcome
Time Frame
Postoperative day 0
Title
Surgery and hepatic resection time
Description
surgery and hepatic resection time
Time Frame
Postoperative day 0
Other Pre-specified Outcome Measures:
Title
30-day mortality
Description
mortality
Time Frame
day 30
Title
Pulmonary complications at day 30
Description
rate of pulmonary complications
Time Frame
day 30
Title
90-day quality of life
Description
quality of life measured with Euro-Quality of Life - 5 Dimensions scale (EQ-5D-5L), composed of: the EQ-5D-5L descriptive system comprising 5 dimensions (mobility, self care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Each level corresponds to 1-digit number expressing the level selected for that dimension the EQ VAS corresponding to a 20 cm vertical, visual analogue scale ranging from 'the best health you can imagine' to 'the worst health you can imagine'
Time Frame
day 90

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients undergoing laparoscopic liver resection Patients ≥ 18 years old Patients willing to participate to the study and able to validly sign informed consent. Exclusion Criteria: Patients presenting a pre-operative platelet count < 50 x 109/L and/or patients with active pre-operative bleeding Patients with planned requirement of continuous neuromuscular blockade monitoring (upon clinical judgement) Known hypersensitivity / previous allergic reactions to study medications Planned total intra-venous anesthesia technique Pregnant or breastfeeding patients.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Giovanni Landoni, Prof.
Phone
+39022643
Ext
6158
Email
landoni.giovanni@hsr.it
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alberto Zangrillo, Prof.
Organizational Affiliation
IRCCS San Raffaele Scientific Institute
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Luigi Beretta, Prof.
Organizational Affiliation
IRCCS San Raffaele Scientific Institute
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Raffaella Reineke, MD
Organizational Affiliation
IRCCS San Raffaele Scientific Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ospedale San Raffaele
City
Milano
ZIP/Postal Code
20132
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Giovanni Landoni, Prof
Phone
+39022643
Ext
6151
Email
landoni.giovanni@hsr.it
First Name & Middle Initial & Last Name & Degree
Giovanni Landoni, Prof.
First Name & Middle Initial & Last Name & Degree
Luigi Beretta, Prof.
First Name & Middle Initial & Last Name & Degree
Alberto Zangrillo, Prof.
First Name & Middle Initial & Last Name & Degree
Roberta Meroni, MD
First Name & Middle Initial & Last Name & Degree
Matteo Marzaroli, MD
First Name & Middle Initial & Last Name & Degree
Raffaella Reineke, MD

12. IPD Sharing Statement

Citations:
PubMed Identifier
16721773
Citation
Ibrahim S, Chen CL, Lin CC, Yang CH, Wang CC, Wang SH, Liu YW, Yong CC, Concejero A, Jawan B, Cheng YF. Intraoperative blood loss is a risk factor for complications in donors after living donor hepatectomy. Liver Transpl. 2006 Jun;12(6):950-7. doi: 10.1002/lt.20746.
Results Reference
background
PubMed Identifier
17382216
Citation
Taketomi A, Kitagawa D, Itoh S, Harimoto N, Yamashita Y, Gion T, Shirabe K, Shimada M, Maehara Y. Trends in morbidity and mortality after hepatic resection for hepatocellular carcinoma: an institute's experience with 625 patients. J Am Coll Surg. 2007 Apr;204(4):580-7. doi: 10.1016/j.jamcollsurg.2007.01.035.
Results Reference
background
PubMed Identifier
21656309
Citation
Yang T, Zhang J, Lu JH, Yang GS, Wu MC, Yu WF. Risk factors influencing postoperative outcomes of major hepatic resection of hepatocellular carcinoma for patients with underlying liver diseases. World J Surg. 2011 Sep;35(9):2073-82. doi: 10.1007/s00268-011-1161-0.
Results Reference
background
PubMed Identifier
27797116
Citation
Moggia E, Rouse B, Simillis C, Li T, Vaughan J, Davidson BR, Gurusamy KS. Methods to decrease blood loss during liver resection: a network meta-analysis. Cochrane Database Syst Rev. 2016 Oct 31;10(10):CD010683. doi: 10.1002/14651858.CD010683.pub3.
Results Reference
background
PubMed Identifier
23269462
Citation
Honda G, Kurata M, Okuda Y, Kobayashi S, Tadano S, Yamaguchi T, Matsumoto H, Nakano D, Takahashi K. Totally laparoscopic hepatectomy exposing the major vessels. J Hepatobiliary Pancreat Sci. 2013 Apr;20(4):435-40. doi: 10.1007/s00534-012-0586-7.
Results Reference
background
PubMed Identifier
26595124
Citation
Kobayashi S, Honda G, Kurata M, Tadano S, Sakamoto K, Okuda Y, Abe K. An Experimental Study on the Relationship Among Airway Pressure, Pneumoperitoneum Pressure, and Central Venous Pressure in Pure Laparoscopic Hepatectomy. Ann Surg. 2016 Jun;263(6):1159-63. doi: 10.1097/SLA.0000000000001482.
Results Reference
background
PubMed Identifier
25125097
Citation
Blobner M, Frick CG, Stauble RB, Feussner H, Schaller SJ, Unterbuchner C, Lingg C, Geisler M, Fink H. Neuromuscular blockade improves surgical conditions (NISCO). Surg Endosc. 2015 Mar;29(3):627-36. doi: 10.1007/s00464-014-3711-7. Epub 2014 Aug 15.
Results Reference
background
PubMed Identifier
31013693
Citation
Oh SK, Kwon WK, Park S, Ji SG, Kim JH, Park YK, Lee SY, Lim BG. Comparison of Operating Conditions, Postoperative Pain and Recovery, and Overall Satisfaction of Surgeons with Deep vs. No Neuromuscular Blockade for Spinal Surgery under General Anesthesia: A Prospective Randomized Controlled Trial. J Clin Med. 2019 Apr 12;8(4):498. doi: 10.3390/jcm8040498.
Results Reference
background

Learn more about this trial

Bleeding in Laparoscopic Liver Surgery

We'll reach out to this number within 24 hrs